Cardiovascular disease and cancer incidence and prevalence have risen over the past few decades to become the leading causes of death. On the one hand, cancer patients will be treated with cardiotoxic chemotherapies; on the other, cardiovascular patients will receive a new diagnosis of cancer and will have to face treatments that may worsen their disease. Moreover, venous thromboembolism can commonly complicate the natural course of patients with cancer in an apparently spontaneous manner or can be triggered by a clinical event such as surgery, invasive procedures, a course of chemotherapy or radiotherapy and is known to be the second cause of death in these patients who also may need to be treated for pre-existing medical conditions or comorbidities. Thus, we introduce the concept of cardiovascular oncology (in the place of cardiooncology) to underline that the problems in this field are not limited to cardiotoxicity of chemotherapies and to the interaction between cardiologists and oncologists, and we focus on the role of the Internist, the only health care giver able to face the multiple problems that cancer patients may undergo.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11739-014-1064-9DOI Listing

Publication Analysis

Top Keywords

cardiovascular oncology
8
cancer patients
8
patients will
8
cancer
5
patients
5
cardiovascular
4
oncology discipline
4
discipline inside
4
inside internal
4
internal medicine?
4

Similar Publications

Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated cancer, and immune checkpoint inhibitors (ICIs) have shown efficacy in its treatment. The combination of chemotherapy and ICIs represents a new trend in the standard care for metastatic NPC. In this study, we aim to clarify the immune cell profile and related prognostic factors in the ICI-based treatment of metastatic NPC.

View Article and Find Full Text PDF

Introduction:  Research on the association between blood groups and cardiovascular diseases (CVDs) in Africa, including Algeria, is notably limited, with a primary focus on blood donors. This narrow scope hinders a comprehensive understanding of the genetic diversity of blood groups and their potential links to CVD risk within the African context. To bridge this knowledge gap, this study proposes to investigate the distribution of blood group genotypes and their association with CVD prevalence, aiming to enhance knowledge within the African context and contribute to global insights into the relationship between blood groups and CVD.

View Article and Find Full Text PDF

Differentiating Choroidal Melanomas and Nevi Using a Self-Supervised Deep Learning Model Applied to Clinical Fundoscopy Images.

Ophthalmol Sci

November 2024

Liverpool Ocular Oncology Research Group, Department of Eye and Vision Science, Institute of Life Course and Medical Sciences (ILCaMS), University of Liverpool, Liverpool, United Kingdom.

Purpose: Testing the validity of a self-supervised deep learning (DL) model, RETFound, for use on posterior uveal (choroidal) melanoma (UM) and nevus differentiation.

Design: Case-control study.

Subjects: Ultrawidefield fundoscopy images, both color and autofluorescence, were used for this study, obtained from 4255 patients seen at the Liverpool Ocular Oncology Center between 1995 and 2020.

View Article and Find Full Text PDF

SGLT2i and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction in Patients With Diabetes.

JACC CardioOncol

December 2024

Cardio-Oncology Program, Division of Cardiovascular Medicine, Department of Medicine, Lahey Hospital and Medical Center, Beth Israel Lahey Health, Burlington, Massachusetts, USA.

Background: Specific cancer treatments can lead to cancer therapy-related cardiac dysfunction (CTRCD). Sodium glucose cotransporter-2 inhibitors (SGLT2is) can potentially prevent these cardiotoxic effects.

Objectives: This study sought to determine whether SGLT2i use is associated with a lower incidence of CTRCD in patients with type 2 diabetes mellitus (T2DM) and cancer, exposed to potentially cardiotoxic antineoplastic agents, and without a prior documented history of cardiomyopathy or heart failure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!